We investigate the relationship between the various parameters in the Monaco MLC model and dose calculation accuracy for an Elekta Agility MLC. The vendor‐provided MLC modeling procedure — completed first with external vendor participation and then exclusively in‐house — was used in combination with our own procedures to investigate several sets of MLC modeling parameters to determine their effect on dose distributions and point‐dose measurements. Simple plans provided in the vendor procedure were used to elucidate specific mechanical characteristics of the MLC, while ten complex treatment plans — five IMRT and five VMAT — created using TG‐119‐based structure sets were used to test clinical dosimetric effects of particular parameter choices. EDR2 film was used for the vendor fields to give high spatial resolution, while a combination of MapCHECK and ion chambers were used for the in‐house TG‐119‐based procedures. The vendor‐determined parameter set provided a reasonable starting point for the MLC model and largely delivered acceptable gamma pass rates for clinical plans — including a passing external evaluation using the IROC H&N phantom. However, the vendor model did not provide point‐dose accuracy consistent with that seen in other treatment systems at our center. Through further internal testing it was found that there existed many sets of MLC parameters, often at opposite ends of their allowable ranges, that provided similar dosimetric characteristics and good agreement with planar and point‐dose measurements. In particular, the leaf offset and tip leakage parameters compensated for one another if adjusted in opposite directions, which provided a level curve of acceptable parameter sets across all plans. Interestingly, gamma pass rates of the plans were less dependent upon parameter choices than point‐dose measurements, suggesting that MLC modeling using only gamma evaluation may be generally an insufficient approach. It was also found that exploring all parameters of the very robust MLC model to find the best match to the vendor‐provided QA fields can reduce the pass rates of the TG‐119‐based clinical distributions as compared to simpler models. A wide variety of parameter sets produced MLC models capable of meeting RPC passing criteria for their H&N IMRT phantom. The most accurate models were achievable using a combination of vendor‐provided and in‐house procedures. The potential existed for an over‐modeling of the Agility MLC in an effort to obtain the fine structure of certain quality assurance fields, which led to a reduction in agreement between calculation and measurement of more typical clinical dose distributions.PACS number(s): 87.56.nk, 87.53.Kn, 87.55.km, 87.55.Qr
We describe the commissioning of the first dedicated commercial total body irradiation (TBI) unit in clinical operation. The Best Theratronics GammaBeam 500 is a Co‐60 teletherapy unit with extended field size and imaging capabilities. Radiation safety, mechanical and imaging systems, and radiation output are characterized. Beam data collection, calibration, and external dosimetric validation are described. All radiation safety and mechanical tests satisfied relevant requirements and measured dose distributions meet recommendations of American Association of Physicists in Medicine (AAPM) Report #17. At a typical treatment distance, the dose rate in free space per unit source activity using the thick flattening filter is 1.53 × 10−3 cGy*min−1*Ci−1. With a 14,000 Ci source, the resulting dose rate at the midplane of a typical patient is approximately 17 and 30 cGy/min using the thick and thin flattening filters, respectively, using the maximum source to couch distance. The maximum useful field size, defined by the 90% isodose line, at this location is 225 × 78 cm with field flatness within 5% over the central 178 × 73 cm. Measured output agreed with external validation within 0.5%. End‐to‐end testing was performed in a modified Rando phantom. In‐house MATLAB software was developed to calculate patient‐specific dose distributions using DOSXYZnrc, and fabricate custom 3D‐printed forms for creating patient‐specific lung blocks. End‐to‐end OSLD and diode measurements both with and without lung blocks agreed with Monte Carlo calculated doses to within 5% and in‐phantom film measurements validated dose distribution uniformity. Custom lung block transmission measurements agree well with design criteria and provide clinically favorable dose distributions within the lungs. Block placement is easily facilitated using the flat panel imaging system with an exposure time of 0.01 min. In conclusion, a novel dedicated TBI unit has been commissioned and clinically implemented. Its mechanical, dosimetric, and imaging capabilities are suitable to provide state‐of‐the‐art TBI for patients as large as 220 cm in height and 78 cm in width.
Cediranib demonstrated significant anti-tumour activity in first line, treatment-naive mRCC, with efficacy parameters comparable to the other approved agents (sunitinib and pazopanib) in this setting. The main toxicities were fatigue, diarrhea and hypertension. Based on these encouraging results, further evaluation of cediranib in mRCC at a more tolerable dose of 30 mg daily appears warranted.
Purpose: To evaluate the magnitude of interobserver variability in pretreatment image registration for lung stereotactic body radiation therapy patients in aggregate and within 3 clinical subgroups and to determine methods to identify patients expected to demonstrate larger variability. Methods and Materials: Retrospective image registration was performed for the first and last treatment fraction for 10 lung stereotactic body radiation therapy patients by 16 individual observers (5 physicians, 6 physicists, and 5 therapists). Registration translation values were compared within and between subgroups overall and between the first and the last fractions. Four metrics were evaluated as possible predictors for large interobserver variability. Results: The mean 3-dimensional displacement vector for all patients over all comparisons was 2.4 ± 1.8 mm. Three patients had mean 3-dimensional vector differences >3 mm. This cohort of patients showed a significant interfraction difference in variance ( P value = .01), increasing from first fraction to last. A significant difference in interobserver variability was observed between physicians and physicists ( P value < .01) and therapists and physicists ( P value < .01) but not between physicians and therapists ( P value = .07). Three of the 4 quantities evaluated as potential predictive metrics showed statistical correlation with increased interobserver variation, including target excursion and local target/lung contrast. Conclusion: Variability in pretreatment image guidance represents an important treatment consideration, particularly for stereotactic body radiation therapy, which employs small margins and a small number of treatment fractions. As a result of the data presented here, we have initiated weekly “registration rounds” to familiarize all staff physicians with the target and normal anatomy for each stereotactic body radiation therapy patient and minimize interobserver variations in image registration prior to treatment. The metrics shown here are capable of identifying patients for which large interobserver variations would be anticipated. These metrics may be used in the future to develop thresholds for additional interventions to mitigate registration variations.
To develop a compact, proof-of-concept kilovoltage intensity modulated radiotherapy platform to deliver contrast-enhanced radiotherapy (CERT). Methods: The proof-of-concept requirements were threefold: (i) develop a compact means to generate a kilovoltage x-ray broadbeam capable of targeting the K-edge of heavy metal contrast, (ii) investigate the potential clinical application of such a beam in silico, and (iii) construct a limited working prototype of the platform to identify weaknesses in the approach. The x-ray broadbeam was created with a standard kilovoltage x-ray tube heavily filtered with 0.156 mm tungsten. Depth dose and treatment characteristics of the beam were investigated using GEANT4 Monte Carlo framework. The working prototype included a miniaturized multi-rod collimator (MRC) constructed with tungsten carbide rods, 3D-printed gear rack, and an in-house GUI/microprocessor assembly. Measurements of simulated treatments were made with EBT3 radiochromic film. Results: Monte Carlo simulations of pseudo-clinical treatments on a homogeneous spherical Lucite phantom produced dose distributions that indicated surface dose was less than target dose. When simulated-bone was added to the calculations, dose-to-bone was found to be the probable limiting factor in clinical treatment. Nevertheless, when iodine contrast enhancement was accounted for, dose was escalated in the tumor compared to standard megavoltage treatments even with dose-to-bone limitations. Experimentally, after commissioning the MRC and calibrating the radiochromic film, surface dose was compared to maximum dose measured on each film. Surface dose measurements were higher than those in a megavoltage beam, but below the skin toxicity threshold. Dose at depth was reasonable despite increased beam attenuation at these energies from photoelectric interactions in bone. IMRT and non-coplanar dose falloffs around the target were steeper than kV 3D conformal dose falloff. Conclusions: The compact kilovoltage treatment platform presented here proved clinically feasible in both simulation and measurement. It is reasonable to pursue this modality further as a potential CERT platform.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.